

LISTING OF THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in this application.

1-98. (Canceled)

99. (New) A method of treating fibromyalgia syndrome comprising administering to a patient in need thereof an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with gabapentin, pregabalin, pramipexole, l-DOPA, tizanidine, clonidine, tramadol, morphine, codeine or carbamazepine.

100. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with gabapentin.

101. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with pregabalin.

102. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with pramipexole.

103. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with l-DOPA.

104. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with tizanidine.

105. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with clonidine.

106. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with morphine.

107. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with codeine.

108. (New) The method of claim 99, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with carbamazepine.

109. (New) A method of treating chronic fatigue syndrome comprising administering to a patient in need thereof an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with milnacipran, or a pharmaceutically acceptable salt thereof, in combination with gabapentin, pregabalin, pramipexole, l-DOPA, tizanidine, clonidine, tramadol, morphine, codeine or carbamazepine.

110. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with gabapentin.

111. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with pregabalin.

112. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with pramipexole.

113. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with l-DOPA.

114. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with tizanidine.

115. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with clonidine.

116. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with morphine.

117. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with codeine.

118. (New) The method of claim 109, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with carbamazepine.

119. (New) A method of treating pain comprising administering to a patient in need thereof an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with milnacipran, or a pharmaceutically acceptable salt thereof, in combination with gabapentin, pregabalin, pramipexole, l-DOPA, tizanidine, clonidine, tramadol, morphine, codeine or carbamazepine.

120. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with gabapentin.

121. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with pregabalin.

122. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with pramipexole.

123. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with l-DOPA.

124. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with tizanidine.

125. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with clonidine.

126. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with morphine.

127. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with codeine.

128. (New) The method of claim 119, wherein the milnacipran, or a pharmaceutically acceptable salt thereof, is administered in combination with carbamazepine.